by Prateek Chopra | June 24, 2026 | Diabetes Conferences | ADA 2026
Study Objective
- Continuous glucose monitoring (CGM) has demonstrated benefits in insulin-treated type 2 diabetes (T2D), but evidence in individuals not receiving insulin therapy remains limited.
- The CONNECT trial was designed to evaluate the effectiveness of CGM in adults with non-insulin-treated T2D (T2D-NIT).
Trial Design
- This multicenter randomized controlled trial enrolled 283 adults with T2D-NIT and HbA1c ≥7.5%.
- Participants were recruited from 21 primary care practices across the United States.
- Individuals were randomized 1:1 to receive either Dexcom G7 CGM or routine care for 26 weeks.
Study Assessments
- Blinded CGM data were collected at baseline in both groups.
- Additional blinded CGM assessments were performed at Weeks 4, 13, and 26 in the routine care group.
- Participants in the CGM arm used unblinded CGM continuously throughout the study.
- The primary endpoint was the change in HbA1c from baseline to Week 26.
Baseline Characteristics
- Mean age: 60 ± 12 years.
- Minority racial or ethnic groups: 32%.
- Mean HbA1c: 8.8 ± 1.2%.
- HbA1c ≥9%: 31% of participants.
- Mean time in range (70–180 mg/dL): 30 ± 25%.
Baseline Medication Use
- 40% of participants were receiving an incretin mimetic (GLP-1 receptor agonist or GLP-1/GIP receptor agonist).
- 37% were receiving an SGLT2 inhibitor.
- Mean HbA1c was:
- 8.8 ± 1.0 among incretin mimetic users.
- 8.6 ± 1.0 among SGLT2 inhibitor users.
- 9.0 ± 1.5 among participants receiving neither therapy.
Clinical Implications
- Many adults with T2D-NIT in primary care remain above recommended glycemic targets.
- A substantial proportion are not receiving incretin-based therapies or SGLT2 inhibitors despite suboptimal glycemic control.
- The CONNECT trial will provide important evidence regarding the potential role of CGM in improving diabetes management in this population.
Baseline findings from the CONNECT trial highlight persistent gaps in glycemic management among adults with non-insulin-treated T2D. The ongoing study will determine whether CGM can improve glycemic outcomes and support more effective diabetes management in routine primary care settings.